Press Releases April 30, 2026 05:36 PM

Methanex Reports on Annual General Meeting of Shareholders

Methanex Holds Annual General Meeting Approving All Proposals and Reappoints Auditor

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
MEOH

Methanex Corporation announced the results of its Annual General Meeting where shareholders voted overwhelmingly in favor of director elections, executive compensation advisory vote, and reappointment of KPMG LLP as auditor. Votes demonstrated strong shareholder support with high participation rates.

Methanex Reports on Annual General Meeting of Shareholders
MEOH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • All director nominees were elected with over 99% votes in favor, showing strong shareholder confidence in Methanex's leadership.
  • KPMG LLP was reappointed as auditor with majority shareholder approval, indicating continuity in financial oversight.
  • The advisory vote on executive compensation was approved by 97.86% of shareholders, reflecting satisfaction with management's pay structure.
  • This event impacts the chemical sector, particularly companies involved in methanol production and broader industrial chemicals markets.

VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Methanex Corporation (TSX:MX) (Nasdaq:MEOH) announced, in accordance with Toronto Stock Exchange requirements, the voting results from its Annual General Meeting held on April 30, 2026 in Vancouver, British Columbia.

Voting Results from Annual General Meeting

A total of 64,397,180 common shares were voted at the meeting, representing 83.27% of all outstanding shares. Shareholders voted in favour of all items of business before the meeting, including the election of all director nominees as follows:

DirectorVotes For% of
Votes
For
Votes
Against
% of
Votes
Against
Doug Arnell62,995,18099.60%251,3330.40%Jim Bertram63,050,27499.69%196,2390.31%Paul Dobson62,753,10699.69%193,4070.31%Maureen Howe62,863,97099.40%382,5530.60%Don Marchand63,214,72899.95%31,7850.05%Leslie O’Donoghue62,906,89999.46%339,5750.54%Roger Perreault62,831,55399.34%414,9590.66%Kevin Rodgers62,943,31599.52%303,1960.48%John Sampson62,830,83899.34%415,6740.66%Rich Sumner63,213,78199.95%32,7320.05%Benita Warmbold62,674,62199.10%571,8900.90%Xiaoping Yang63,069,42199.72%177,0910.28%     

Appointment of Auditors

KPMG LLP, Chartered Professional Accountants, was re-appointed as auditor of Methanex.

Votes For (percent): 76.52%
Votes Withheld (percent): 23.48%

Advisory Vote on Executive Compensation

A non-binding advisory vote to accept Methanex’s approach to executive compensation as disclosed in the Information Circular dated March 9, 2026 was approved.

Votes For (percent): 97.86%
Votes Against (percent): 2.14%

Methanex is a Vancouver-based, publicly traded company and is the world's largest supplier of methanol globally. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol "MX" and on the Nasdaq Global Select Market in the United States under the trading symbol "MEOH". Methanex can be visited online at www.methanex.com.

Inquiries:
Robert Winslow
Investor Relations
Methanex Corporation
604-661-2600 or Toll Free: 1-800-661-8851
www.methanex.com


Risks

  • A notable portion of votes (23.48%) withheld for auditor appointment could indicate some shareholder concerns around auditing or governance.
  • As a non-binding advisory vote, the executive compensation approval does not guarantee no future shareholder dissent in pay matters.
  • Market reaction could be tempered due to the routine nature of AGM results without new strategic initiatives or financial disclosures.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026